Weight Management
Cagrilintide
10mg · 5mg
Long-acting amylin analogue studied for appetite regulation and metabolic support.
Mechanism
Cagrilintide is a novel, long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It activates amylin receptors (AMY1 and AMY3) in the area postrema and other brainstem regions involved in satiety signaling. This activation modulates gastric emptying kinetics, reduces glucagon secretion, and engages central satiety signaling pathways. Its acylation with a C18 fatty diacid enables albumin binding, extending its half-life to support once-weekly dosing. Studies have examined dose-dependent effects on metabolic signaling pathways through amylin receptor activation.
What the literature has looked at
- Studies have investigated dose-dependent amylin receptor pharmacology over extended periods
- Research has examined combination approaches with GLP-1 receptor agonists (CagriSema)
- Studies have explored its effects on glycemic signaling and satiety pathway activation
- Research has assessed dual amylin-incretin receptor co-agonist approaches for metabolic pathway modulation
Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.
Cited work
Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
Research investigated cagrilintide-mediated amylin receptor activation and its dose-dependent effects on metabolic signaling pathways, with a dose-response relationship observed across all study groups.
Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.
Research examined the pharmacodynamic interaction of combined amylin and GLP-1 receptor activation, suggesting complementary mechanisms of action on metabolic signaling pathways.
Properties
- cas Number
- 1415456-99-3
- type
- Peptide (acylated amylin analog)
Carries your code if you arrived with one — check the badge in the header.